—

Crinetics Pharmaceuticals Inc (CRNX) — the peer cohort

As of 2026-10-26 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Crinetics Pharmaceuticals Inc ranks 7 of 7 in its cohort on the Closelooknet composite (49/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
CRNX Crinetics Pharmaceuticals Inc 49 99 21 5 — —
HALO Halozyme Therapeutics Inc 74 98 94 48 ok 0.1%
BION.SW BB Biotech AG 73 62 96 82 info 13.3%
UCB.BR UCB SA 65 65 70 54 info 6.2%
ARGX.BR Argen-X 64 71 75 29 info 15.7%
ONC BeiGene, Ltd. 64 84 64 30 ok 4.6%
ARGX argenx NV ADR 63 66 74 29 info 19%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-26

Quick answers

Who are Crinetics Pharmaceuticals Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BB Biotech AG (BION.SW), UCB SA (UCB.BR), Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), argenx NV ADR (ARGX).

How does CRNX score against its peers?

Crinetics Pharmaceuticals Inc's composite reads 49/100, ranking 7 of 7 in its cohort as of 2026-10-26; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.